Stay updated with breaking news from Year Analysis. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Conference call scheduled for 4:30 p.m. EDT today Exclusive distribution agreement signed with Shanghai Medtronic Zhikang Medical Devices Co. Ltd. for...
Conference call scheduled for 4:30 p.m. EDT today Exclusive distribution agreement signed with Shanghai Medtronic Zhikang Medical Devices Co. Ltd. for...
Power Conversion System (PCS) Electrochemical Energy Storage System Market Projected Value Of US$ 13,211.4 Mn, with Indexing A CAGR Of 24.9%.
Conference call scheduled for 8:30 am ET today hosted by management with guest Dr. Richard Fine Increased commercial activity in the U.S. and globally with...
Autoimmune toxicities, while common following treatment with cancer immunotherapies, are not well-characterized in patients treated with BRAF/MEK inhibitors. Emerging data suggest that autoimmune effects may be linked with superior responses to both treatment modalities; however, there is little evidence describing mechanisms of immune-related toxicity for patients on BRAF/MEK inhibitors. Here we describe the experience of a 59-year-old HLA-A2, A29, B27-positive male patient with recurrent/metastatic melanoma. After progression on checkpoint inhibitor therapy, he was treated with dabrafenib/tr...